# enGene

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/engene

- Industry: Biotechnology
- Headquarters: Saint-Laurent, Canada
- Website: https://engene.com/
- Total disclosed funding: $25M
- Latest round: Series B (Jan 26, 2015)
- Investors on record: 4

## About

Established in 1999 and based in Quebec, Canada, enGene Inc. operates as a clinical-stage genetic medicines company. The company was founded by its CTO, Anthony T. Cheung. In February 2024, enGene Inc. agreed to raise USD 200 million in PIPE funding from Adage Capital Management, Blue Owl Capital, Boxer Capital, Commodore Capital, and Cormorant Asset Management. The transaction is expected to close on February 16, 2024, subject to customary closing conditions. The company trades on the Nasdaq under the ticker symbol ENGN. As of 2024, the company is led by its CEO Ron Cooper.

enGene develops gene therapies. The company's primary technology is a non-viral gene delivery platform called DDX, which enables the delivery of multiple genes directly to mucosal tissues and other organs. The firm’s lead product, EG-70, is a non-viral immunotherapy in development for the treatment of non-muscle-invasive bladder cancer.

The company plans to use the funds raised in February 2024 for the development of EG-70, a genetic medicine therapeutic candidate evaluated in an ongoing pivotal study for BCG-unresponsive NMIBC, R&D purposes, working capital, and general corporate purposes.

## Funding rounds

- Series B, Jan 26, 2015, $11M — Forbion, Pharmstandard International S.A., Fonds de solidarite FTQ, Lumira Ventures
- Series A, Aug 1, 2013, $13M — Lumira Ventures

## Investors

- Lumira Ventures (https://capitalatlas.ai/funds/lumira-ventures) — Series A, Series B
- Forbion (https://capitalatlas.ai/funds/forbion) — Series B
- Pharmstandard International S.A. — Series B
- Fonds de solidarite FTQ (https://capitalatlas.ai/funds/fonds-de-solidarite-ftq) — Series B